IBRX Earnings

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

Published August 05, 2025 at 11:00 AM

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced its financial results for the fiscal quarter and six months ended June 30, 2025. In the second quarter of 2025, ImmunityBio reported $26.4 million in revenue, representing a 60% increase from $16.5 million in the first quarter of 2025. This growth reflects continued commercial traction of ANKTIVA in combination with BCG in BCG-unresponsive NMIBC with carcinoma in situ (CIS) w

Related Questions

What are the market expectations for ANKTIVA's market penetration and pricing in the BCG‑unresponsive NMIBC segment? How does ImmunityBio's 246% unit growth since the J‑code compare to historical growth rates of comparable immunotherapy firms? How will the 60% quarter‑over‑quarter revenue increase affect ImmunityBio's valuation and upside potential? What are the anticipated cash flow implications of the current growth trajectory for the company's balance sheet and liquidity position? What are potential regulatory or reimbursement challenges that could affect future revenue streams from ANKTIVA? Are there any forward‑looking guidance updates or product pipeline milestones that could drive further price movement? What are the projected commercial rollout timelines for ANKTIVA with BCG in the next 12–24 months? How might the earnings results impact the stock’s short‑term technical momentum and trading volume? How does ImmunityBio's Q2 net income and cash burn compare to its peers in the oncology immunotherapy space? Is the $43 million year‑to‑date sales figure in line with analyst forecasts, and what is the variance to consensus estimates?